Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Heart Failure
 More »

  • SciClone Bringing Zensun's Heart Failure Drug to China
    for the treatment of patients with intermediate to advanced chronic heart failure (CHF). ... reverse ventricular remodeling, and increase the survival of heart failure patients. ...
    5-17-2013
  • Mass Spec Provides Peek into PTMs
    as the elucidation of their important roles in the development of diabetes and heart failure has relied on the use of chemoenzymatic labeling for the enrichment of protein ...
    5-15-2013
  • Forest Labs Bets Up To $460M on Trevena Heart Failure Drug
    Forest Laboratories will join Trevena in developing its clinical-stage acute heart failure ... trial, set to start by year's end, of TRV027 in acute decompensated heart failure (ADHF). ...
    5-9-2013
  • BMS Partners Again with Ambrx, in Up-to-$112M-and-Up ADC Collaboration
    the Fibroblast Growth Factor 21 (FGF-21) protein, for potentially treating type 2 diabetes; the other focused on the Relaxin hormone, for potentially treating heart failure. ...
    5-3-2013
  • Gene Critical for Heart Regeneration
    If done successfully, this ability could introduce a new era in treatment for heart failure." The study was published online yesterday in Nature, in a paper titled "Meis1 regulates ...
    4-18-2013
  • AstraZeneca Raises S&P Eyebrows
    ... Last year alone, AZ lost $3 billion in sales for Seroquel IR, plus a combined $1 billion due to regional losses of patent protection for Nexium, blood pressure/heart failure drug ...
    4-9-2013
  • Roche and Isis Pharmaceuticals Set Sights on Huntington's
    Symptoms usually appear between the ages of 30 to 50, and worsen over a 10 to 25 year period. Ultimately, the weakened individual succumbs to pneumonia, heart failure or other ...
    4-8-2013
  • BMS Shores Up R&D after Trial Failure, Plavix Patent Loss
    It stumbled last year when hep C candidate BMS-986094 (094) failed a Phase IIb study that was suspended after a heart failure death in one of 30 patients receiving the highest ...
    4-8-2013
  • Astellas, Ambrx Launch Up-To-$300M ADC Partnership
    With BMS, for example, Ambrx is developing Phase I drug candidate ARX618 for diabetes, and the preclinical candidate Relaxin for heart failure. Ambrx' lead product, ARX201, is a ...
    4-5-2013
  • Is This Gene Therapy's Breakout Moment?
    And in February 2012, Celladon completed a $43 million equity financing to advance clinical development of its lead drug candidate MYDICAR for heart failure. Pharma Involvement ...
    4-1-2013
  • Aastrom Starts Layoffs, Slashes Expenses as Phase III Trial Halted
    ... heart tissue in a murine model of heart failure. "These findings strongly support the ... injections to patients with advanced heart failure due to ischemic DCM. The primary ...
    3-27-2013
  • Is This Gene Therapy's Breakout Moment?
    And in February 2012, Celladon completed a $43 million equity financing to advance clinical development of its lead drug candidate MYDICAR for heart failure. Pharma Involvement ...
    3-4-2013
  • Top 10 VC & Biopharma Equity Deals of 2012
    investor Purpose: Advance lead investigational product candidate Mydicar® for heart failure. #9. SFJ Pharmaceuticals Equity invested: $56.5 million 2 Type of equity: Venture ...
    2-8-2013
  • Top 10 Clinical Trial Failures of 2012
    ... Drug administration in Phase IIb study suspended following the occurrence of heart failure in one patient who received the highest daily dose, 200 mg, in combination with ...
    2-1-2013
  • Drug Repurposing Rekindles Promise
    ... Anecdotal experience led to repurposing certain beta-blockers for migraine prophylaxis and the treatment of congestive heart failure (CHF). Although CHF for many years was a ...
    1-25-2013
  • More »

    Journal Articles

  • Costs and Benefits of Personalized Healthcare for Patients with...
    Stefan Sohn, Thomas M. Helms, Jörg T. Pelleter, Axel Müller, Annett I. Kröttinger, Oliver Schöffski
    Telemedicine and e-Health
    Costs and Benefits of Personalized Healthcare for Patients with Chronic Heart Failure in ... slight limitation according to the NYHA classification for the extent of heart failure). ...
  • Transforming Growth Factor- β Inhibits Coxsackievirus-Mediated...
    Marc S. Horwitz, Maria Knudsen, Alex Ilic, Cody Fine, Nora Sarvetnick
    Viral Immunology
    Clinical myocarditis is a precursor to dilated cardiomyopathy and a principal cause of heart failure. Nearly 30% of all recently diagnosed cases of myocarditis are attributable to ...
  • Is Cardiac Consultation with Remote-Controlled Real-Time Echocardiogra...
    Curt Löfgren, Kurt Boman, Mona Olofsson, Lars Lindholm
    Telemedicine and e-Health
    The CARdiac echo consultation on DISTAnce (CARDISTA) was evaluated in three primary healthcare centers in Sweden. The clinical focus of the evaluation was on heart failure. Using a ...
  • St. Vincent's Home Telehealth for Congestive Heart Failure Patients
    Pamela Whitten, Alicia Bergman, Mary Ann Meese, Karin Bridwell, Kim Jule
    Telemedicine and e-Health
    Vincent's Home Telehealth for Congestive Heart Failure Patients Telemedicine and e-Health ... Fifty congestive heart failure patients reported significant improvement with regard to ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll